Cephalon Provigil ADHD Trial Failure Cuts Anesta Merger Value By One-Third
Cephalon is experiencing stock hyperactivity disorder following a negative clinical trial report in a preliminary study of Provigil for use in ADHD.
More from Archive
More from Pink Sheet
• By
Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.
• By
Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.
• By
The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.